scout
Opinion|Videos|March 12, 2024

KEYNOTE B61 Extended Follow Up of Lenvatinib plus Pembrolizumab in nccRCC 1L

An expert discusses key data points from the KEYNOTE B61 extended follow up of Lenvatinib plus pembrolizumab in first line setting in non-clear cell renal cell carcinoma.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME